CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 30 target
Drug / intervention
Valbenazine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07111988
NCT07111988Phase 2Not Yet Recruiting
CompareCT.gov

Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial

University of Chicago·interventional·Posted Aug 8, 2025·Updated Jun 10, 2026

In Brief

A Phase 2 clinical trial evaluating Valbenazine and Placebo for Obsessive-Compulsive Disorder. Not yet recruiting, targeting 30 participants.

Detailed Summary

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
Countries--
CollaboratorsNeurocrine Biosciences

Timeline

Phase 2Not Yet Recruiting
202620272028
First PostedAug 8, 2025
Enrollment StartJun 1, 2026
Primary CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 11 months agoPrimary completion in 1.4 years

Interventions

Valbenazinedrug

Selective vesicular monoamine transporter 2 (VMAT2) inhibitor

Placebodrug

Pill that contains no medicine